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Abstract 
Objectives. Extracorporeal Life Support (ECLS) is an emerging option to treat selected 
patients with cardiac arrest refractory to cardiopulmonary resuscitation (CPR). Our primary 
objective was to determine the mortality at 30 days and at hospital discharge among adult 
patients receiving veno-arterial ECLS for refractory cardiac arrest. Our secondary 
objectives were to determine the one-year survival and the health-related quality-of-life, 
and to examine factors associated with 30-days mortality.  
Methods. In a retrospective, single-center investigation within a tertiary referral center, we 
analyzed the prospectively collected data of 49 patients rescued from refractory cardiac 
arrest through emergent implantation of ECLS (E-CPR) (18.1% of our overall ECLS 
activity 2005-2013). E-CPR was implanted in-hospital and during ongoing external cardiac 
massage in all cases. A prospective follow-up with administration of the SF-36 
questionnaire was performed.  
Results. Mean age was 47.6 ± 1.6 years, out-of-hospital cardiac arrest occurred in 12% of 
cases, average low-flow time was 47.2 ± 33 min; causes of cardiac arrest were heart 
disease (61.2%), trauma (14.3%), respiratory disease (4.1%), sepsis (2%) and 
miscellaneous (18.4%).  Primary objective: rates of survival at E-CPR explantation and at 
30 days were 42.9% and 36.7%; brain death occurred in 24.5% of cases. Secondary 
objectives: increased SAPS score, higher serum lactates and lower body temperature at 
the time of implantation were associated with 30-days mortality. Bridge to heart 
transplantation or implantation of long-term ventricular assist device was performed in 
8.2%. There were no cases of mortality during the follow-up after discharge (36.7% 
survival; average follow-up was 15.6 ± 19.2 months). Average Physical and Mental 
Component Summary scores (SF-36 questionnaire) were 45.2 ± 6.8 and 48.3 ± 7.7 among 
survivors. 
Conclusions. E-CPR is a viable treatment for selected patients with cardiac arrest 
refractory to CPR. In our series, about one third of rescued patients were alive at 6 months 
and presented quality-of-life scores comparable to those previously observed in patients 
treated with ECLS.  
ABSTRACT WORD COUNT : 313 
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Central Message 
 E-CPR can achieve 36.7% survival at mid-term in selected patients with cardiac arrest 
refractory to cardiopulmonary resuscitation. 
Perspective 
 Selection of patients is pivotal to achieve adequate results with E-CPR. Among 
survivors, quality-of-life at follow-up was comparable than previously obtained after ECLS 
therapy. A multidisciplinary debate is needed to establish evidence-based protocols and 
justified employment of ECLS. The diffusion of ECLS needs to take into account 
organizational, economic, ethical and learning curve issues. 
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Introduction 
Extracorporeal Life Support (ECLS) therapy is an option for severe cardiac or 
cardiopulmonary failure. ECLS consists in an extracorporeal circulation circuit equipped 
with a rotary blood pump and a blood hollow-fiber oxygenator. There is cumulating 
evidence over the usefulness of ECLS in improving the survival of selected patients with 
cardiac arrest refractory to advanced cardiopulmonary resuscitation [1] (E-CPR). The 
survival at 30 days after ECLS implantation in such patients reportedly ranges between 
24% and 36% [2, 3, 4]. Other series have reported survival rates up to 50%. Nonetheless, 
these studies are difficultly comparable to ours since they included also patients who
received ECLS implantation not during cardiopulmonary resuscitation (CPR), or in-hospital 
cardiac arrest cases only [5]. Nonetheless, there are few evidence available over the 
clinical outcomes after hospital discharge of patients who survived refractory cardiac arrest 
and failed CPR thanks to ECLS therapy.  This population consists of critically ill patients 
with major rates of severe in-hospital complications. Therefore, not only the vital status of 
these patients late after hospital discharge needs to be clarified, but also their quality of 
life. The latter information are lacking even from the analysis of major multicentre registries
[6], despite they may be important in clinical decision-making and allocation of resources. 
Projected quality of life is evidenced in the recent European guidelines as one foremost 
aspect to be considered while evaluating the indication to ECLS in acute heart failure [6]. 
However, such judgment poses major difficulties among patients with refractory 
cardiogenic shock due to emergent presentation, frequent uncertainty of the extent of brain 
damage, and coexistence of comorbidities. The literature lacks specific information over 
this issue as well. 
The purpose of the present investigation was twofold. The first objective was to clarify the 
mortality at 30 days and at hospital discharge in adult patients receiving veno-arterial 
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ECLS for refractory cardiac arrest (E-CPR). The secondary objective was to clarify the 
one-year survival and the perceived health-related quality-of-life in these patients, and to 
identify factors associated with 30-day mortality. 
Patients and Methods 
Patients’ selection and technique of ECLS implantation. 
Between January 2005 and October 2013, 270 patients received veno-arterial ECLS at our 
Institution. Of these, 49 (18.1%) were treated on an emergent basis for cardiac arrest 
refractory to conventional CPR. All the patients included in the present study received
ECLS implantation during ongoing CPR. We excluded the patients who had ECLS in the 
immediate post-cardiotomy circumstances due to the impossibility to wean from cardio-
pulmonary bypass, and the patients receiving veno-venous ECLS for primary lung 
dysfunction. No patient received E-CPR out-of-hospital; nevertheless, some patients who 
suffered cardiac arrest out-of-hospital and received E-CPR within our center were included 
(N=6, 12%). The cases satisfying the above criteria were retrospectively selected from our 
database and served for subsequent analyses. 
The indications to E-CPR were established in compliance with the current 
recommendations [6] by a multidisciplinary team including at least one surgeon and two 
physicians. We adopted the algorithm proposed by Combes and associates [7]. Briefly, E-
CPR was contraindicated in case of no-flow time exceeding 5 minutes or unwitnessed 
cardiac arrest, in case of total expected duration of low-flow exceeding 100 minutes, in 
case of end-expiratory CO2 concentration lower than 10 mmHg or of asystole on ECG. 
The indication to E-CPR was discussed also in perspective with the patient’s known 
comorbidities and life expectancy. The notion of intoxication or hypothermia (32°C) 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT

	
represented an element in favor of the indication to E-CPR during enrollment of the 
present series. The implanting team included two surgeons (senior and resident), a scrub-
nurse and a perfusionist. All material is available on a dedicated trailer, allowing full 
autonomy for prompt displacement of the team within the hospital facilities. Implantation of 
E-CPR was performed through longitudinal skin incision at the right groin and preparation 
of the anterior face of the common femoral artery and vein. The femoral vessels were 
neither encircled nor clamped. The percutaneous technique was never employed, in order 
to facilitate rapid institution of E-CPR and avoid the difficulties to appreciate pulses and 
backflow due to marginal hemodynamic conditions. Cannulation was performed using the 
Seldinger technique; arterial inflow was obtained through a 16 to 20 Fr cannula (Edwards 
Lifesciences Inc., Irvine, CA), and venous drainage was achieved with an 18 to 24 Fr 
cannula (Edwards Lifesciences Inc., Irvine, CA). In event of failed cannulation due to 
extensive arterial calcifications or impossibility to adequately advance the guidewires, the 
left groin was explored. Distal perfusion of the lower limb was assured through the 
superficial femoral artery using a 6-to-10 Fr cannula (Seldinger technique) connected to a 
side branch of the arterial inflow line. During ECLS therapy, heparin was administered 
through a central venous line in order to maintain an activated clotting time between 150 
and 180s; in the presence of hemorrhagic complications, the dose of heparin was adjusted 
or the administration was temporary withheld. Efficacy of ECLS therapy was monitored by 
periodical assessment of arterial and central venous pressures, urine output, systemic 
oxygen saturation and venous lactate concentration, as reported in the current 
recommendations [8]. Pump speed was adjusted in order to keep the cardiac index within 
the 2.2-2.8 l min-1 m-2 range and to obtain adequate cardiac unloading. Patients on ECLS 
were evaluated on a daily basis by a multidisciplinary team including surgeons, 
cardiologists and anesthesiologists. Transthoracic and/or transesophageal 
echocardiography were employed for verification of cardiac decompression. In event of 
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inadequate left ventricular (LV) unloading and/or occurrence of pulmonary edema, 
adjustment of inotropic drugs (Dobutamine) and/or IABP therapy were adopted. Shift to 
central cannulation and surgical LV unloading through the right upper pulmonary vein or 
main pulmonary artery was considered as a further measure during the earliest part of our 
experience. More recently, the positioning of a transaortic axial flow pump (Impella, 
Abiomed Inc., Aachen, Germany) was considered. The oxygenator and the circuit were 
replaced in case of clot formation within the system or major haemolysis. Whether IABP 
therapy was already in place at the time of E-CPR implantation, it was maintained until end 
of ECLS. Therapeutic hypothermia was performed by at least 24 hours (target: 34°C). 
Weaning from ECLS was considered when partial or complete recovery from cardiac 
dysfunction could be demonstrated on echocardiography, associated with the presence of 
a stable pulsatile blood pressure waveform, and mean blood pressure remaining above 60 
mmHg during a weaning trial (progressive reduction of the ECLS flow until a minimum of 1 
l/min), while receiving minimal or low dose inotropic agents.  
Definitions. 
We defined refractory cardiac arrest as persisting beyond the 30th minute of CPR. 
Etiologies of cardiac arrest were categorized as follows: Cardiac disease (further divided 
into AMI, Cardiomyopathy, Acute myocarditis, Refractory arrhythmia, Acute pulmonary 
embolism), Respiratory disease, Trauma (including hypothermia, suicide attempt, drug 
overdose), Sepsis, and Miscellaneous (those cases which could not be categorized into 
the other groups).  Vascular complications at the site of E-CPR implantation were the need 
to perform at least one additional surgical procedure to revise hemostasis at the site of 
cannulation for ECLS, or to reconstruct/repair the involved vessels. Lower limb ischemia 
was the need to perform at least one additional surgical procedure to relief ischemia 
and/or treat compartmental syndrome. Hemorrhagic complications on ECLS were the 
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need to perform at least one surgical revision for bleeding at a site different than the 
cannulated vessels, and/or to transfuse at least 4 units of concentrated red blood cells to 
treat anemia resulting from bleeding. Complications to on ECLS were grouped according 
to the ELSO registry definitions, as follows: ECLS circuit complications, central nervous 
system complications, cardiac complications, pulmonary complications, infectious 
complications, renal complications, gastrointestinal complications, metabolic 
complications5. Brain death of patients on ECLS had to be declared by at least two 
intensive care medicine specialists in consensus according to the criteria fixed by the 
French law (abolition of all brainstem reflexes, absence of spontaneous ventilation at 
hypercapnia test – PCO2>60 mmHg, and two electroencephalography recordings practiced 
with a 4-hours interval). 
Patients were evaluated using the SAPS score (version 2) at the time of E-CPR 
implantation [9], using the calculator available online at www.sfar.org (website of the 
French Society of Anesthesia and Intensive Care). 
Follow-up and Quality-of-Life assessment. 
A follow-up program for patients receiving ECLS at our Institution was started in April 
2013. Patients who were alive at the time of hospital discharge were contacted 
telephonically by research nurses experienced in the chronic management of patients 
receiving surgical treatment for heart failure. All patients could be contacted and 
interviewed directly. The inquiry included assessment of the functional and vital status, 
adverse events after discharge, and formal evaluation of quality-of-life among survivors 
(administration of the French Version of the Medical Outcomes Study 36-Item Short-Form 
Health Survey, SF-36) [10, 11, 12]. The questionnaire was administered according to 
recommendations [10], and provided a score for each of the following domains: physical 
activity, role limitation, physical pain, general health, vitality, social activity, mental health, 
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physical component summary and mental component summary. The SF-36 questionnaire 
has been previously employed in the evaluation of health-related quality-of-life in patients 
surviving critical illness thanks to ECLS [13], veno-venous extracorporeal membrane 
oxygenation [14], and in patients with advanced heart failure [15, 16, 17]. The SF-36 has 
been also employed to evaluate survivors to cardiac arrest who have not been treated by 
E-CPR [17]. Data were entered into the Rennes ECLS Registry. 
Management of data and statistical analysis. 
Since the beginning of the ECLS program at our Institution, the clinical data pertaining to 
each patient receiving such treatment are prospectively entered in an electronic database. 
This includes all pre- and post-implantation data, major biological and hemodynamic 
parameters, drug therapy and in-hospital complications. The database is regularly checked 
for errors and omissions by dedicated personnel. The prospectively collected data can be
then retrospectively analyzed. IRB approval was obtained. Our study is declared to the 
CLIN online database (Commission Nationale de l’Informatique et des Libertées – French 
National Commission for Informatics and Freedom) according to the French law. 
Continuous data are presented as mean ± standard deviation, and categorical variables as 
percentages. Intergroup comparison was performed using the two-tailed Student’s t test 
for continuous data, and the chi-square test for categorical data. All available baseline 
variables were used for intergroup comparison (about forty variables). Survival analysis 
was conducted according the Kaplan-Meier methodology, and the corresponding survival 
curves were built. Analyses were performed using the SAS software ver. 9.33 for Windows 
(SAS Institute Inc., Cary, NC). 
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Results 
The study workflow is reported in Figure 1. Forty-nine patients received E-CPR (18.1% of 
overall ECLS activity at our Institution). The baseline features of the study population and 
the indications to E-CPR treatment are summarized in Table 1. Most frequently, the 
indication to E-CPR pertained to the Cardiac disease group; among these, AMI was 
prevailing (47% of the 30 patients pertaining to such group). Two patients had baseline 
respiratory disease, which led to anoxic refractory cardiac arrest and required E-CPR. In 
these patients, circulatory and myocardial failure superimposed to pulmonary failure made 
the use of veno-venous ECMO alone insufficient. Biological variables at the time of 
implantation (serum lactate concentration, pH, serum creatinine and markers of end-organ 
damage) underline the critical general conditions of these patients. Average no-flow time 
was 47.2 ± 33 minutes. Average diameter of the arterial and venous cannulae was 19.1 ± 
1.5 Fr and 20.3 ± 2.6 Fr, respectively. 
Twenty-one patients (42.9%) were alive at the time of explantation of ECLS; among these, 
the average duration of support was 6.8 ± 5.8 days. The remaining patients (57.1%) died 
after 2.8 ± 4 days after institution of E-CPR. Three patients deceased within the hospital 
after explantation of ECLS and within the 30th post-implantation day. Causes of death 
were: multiorgan failure in 14 cases (28.6% in the overall population), brain death in 12 
cases (24.5%), and irrecoverable myocardial failure in 2 cases. No further patients died 
within the hospital after the 30th post-implantation day. Thus, 18 patients (36.7% of the 
initial population) were discharged alive from the hospital (average hospital stay: 79.1 ± 
97.6 days). Thromboembolic and hemorrhagic complications were common under ECLS 
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(59.2% cumulative rate). Only one patient experienced an ischemic complication of the 
lower limb (2%). Transfusion with red blood cells, platelets units and fresh frozen plasma 
units was required in 79.1%, 54.2% and 61.2% of cases, respectively. Seven patients 
(14.3%) were concomitantly treated by IABP; among these, 3 received IABP after E-CPR 
implantation in order to facilitate unloading of the LV. Two patients (9.5% of survivors at 
explantation) were successfully bridged to heart transplantation, while two further patients 
received an implantable LVAD. 
At the time of ECLS explantation, a marked improvement of the biological parameters was 
evident: average pH was 7.4 ± 0.1, serum lactates concentration was 2.8 ± 3.3 mmol/L. 
Partial recovery of end-organ damage was disclosed (average serum SGOT 
concentration: 82.3 ± 78.5 IU/L; serum creatinine: 116.8 ± 93 µmol/L). Cardiac function 
was partially recovered as well, the average LVEF being 37% ± 15. Brain death occurred
in 12 cases (24.5% of the entire population, 38.7% of deceased patients). Average 
duration of mechanical ventilation was 7.7 ± 9.2 days. Table 2 compares the major patient-
related variables among survivors and non-survivors at the 30th post-implantation day. 
Higher SAPS score, lower body temperature and higher lactate level at the time of ECLS 
implantation were statistically associated with death before explantation. 
Table 3 compares the rates of bridge to urgent heart transplantation or to LVAD among 
patients who received E-CPR vs. the remaining patients who received veno-arterial ECLS 
in our Institution during the same time period. 
Late Results. 
The follow-up was 94.5% complete (one patient was lost); its average duration was 15.6 ± 
19.2 months. Among the 18 patients who left the hospital alive, none of them was 
deceased at the latest available follow-up. The Kaplan-Meier survival curve (Figure 2) 
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consequently indicates stable survival after the 16th post-implantation day (timepoint of the 
last observed fatal event). Measures of health-related quality-of-life as obtained by the SF-
36 questionnaire among the survivors at follow-up are summarized in Table 4. Our 
patients showed the best scores in the Physical Pain, Social Activity, Mental Health and 
Physical Activity domains, while the average performance was worse in the Vitality 
domain. Figure 3 offers a comparison of the average SF-36 scores obtained in our series 
vs. those previously published for survivors to ARDS through veno-venous ECMO and 
survivors to post-cardiotomy myocardial failure through veno-arterial ECLS. Control data 
are for a French age- and sex-matched population without adverse health conditions [10]. 
Globally, our patients showed lower average SF-36 scores than control patients, but they 
had also better performance than the comparator ECMO/ECLS cohorts. 
Comment 
Since the earliest experiences about E-CPR to rescue refractory cardiac arrest, 30-days 
survival in this complex patients subgroup raised from 24% [12, 19] to about 34% in recent 
times [20] and to 39% in selected populations (MI-related cardiac arrest [1]). Such 
tendency is confirmed herein. We observed a 42.9% survival at ECLS explantation and a 
36.7% survival at both 30 days and hospital discharge. Our series should be compared 
with previously published experiences which included only patients who received ECLS 
during ongoing CPR. Otherwise, the interpretation of previously reported survival rates up 
to 50% [5] may be misleading. Yet, ECLS guarantees a survival advantage over 
conventional CPR if this protracts beyond 10 minutes [21]. Such amelioration may be 
ascribed to improved selection of candidates and growing experience of E-CPR teams. 
Prompt decision-making and effective organization are crucial to achieve survival of these 
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critically ill patients. In fact, anoxic brain death of patients treated with E-CPR appeared to 
be one major threaten in the published experiences [6, 23].  
Causes of death on ECLS support are closely related to the major decision-making issues 
encountered in these patients. Despite the relatively low rate of out-of-hospital cardiac 
arrest in our series (12%), the rate of brain death among the E-CPR recipients remains 
remarkable (24.5% overall). Conversely, multiorgan failure is the most prevalent cause of 
death in our population: end-organ damage induced by cardiogenic shock can be 
reasonably considered as the triggering factor for this ominous condition. Such concept 
underlines the importance of prompt and effective CPR and institution of E-CPR. 
Concordantly, in our study survivors presented a trend towards significantly shorter 
average low-flow time and, additionally, absence of no-flow time. Nonetheless, ECLS itself 
represents a trigger for systemic inflammatory reaction: it has been associated with a 
‘cytokine storm’ (Tumor Necrosis Factor-alpha, TNF-α, Interleukin 8, IL-8, IL-6) which may 
propagate organ injury [23]. Evidence from the animal model suggests that such 
mechanism may also play a role in delayed pulmonary recovery during veno-venous ECLS 
for severe respiratory failure [24]. Interestingly, myocardial failure itself is the less common 
determinant of the final outcome once ECLS has been instituted. Fatal issue due to failed 
electrical recovery from cardiac arrest was observed in 2 cases in our series despite 
effective ventricular unloading. Early termination of support was decided in these cases. 
Patients who present failed recovery of myocardial contractility over the later days may be 
bridged to urgent heart transplantation or to destination LVAD (2 cases each in our series, 
9.5% of the survivors at the 30th day). Nonetheless, rational employment of transplantation 
and VAD resources restrain their use to patients with survivable levels of end-organ 
dysfunction. It has been proposed that recovery from the initial shock-related injury should 
be expected within the 2nd-5th postimplantation day; ECLS-related end-organ injury would 
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become clinically significant in the later days and render end-organ recovery unlikely [25]. 
Non-surviving patients presented higher SAPS score, lower body temperature and higher 
serum lactates at implantation compared to survivors. We observed also a trend towards 
longer low-flow time among non-survivors. Lower blood pH was observed among non-
survivors, although significance was not attained. These data should be interpreted 
cautiously, since no multivariate analysis could be performed. Nonetheless, these 
observations suggest the importance of the degree of end-organ injury in the determinism 
of survival and may support the decision-making.  
In light of worse results, there is controversy over the opportunity of employing E-CPR 
outside the referral Institution for out-of-hospital cardiac arrest [1, 26, 27]. Not only clinical 
factors, but also organizational, public healthcare, economic and ethical issues are 
involved in such controversy. The possibility of sudden cardiac arrest everywhere in the 
territory and the prognostic importance of prompt initiation of support when indicated, 
suggests the diffusion of ECLS equipment and techniques in all peripheral hospital who 
have an ICU available. This model would better guarantee a uniform respect of the 
citizens’ right to access lifesaving care, even though the cardiac arrest occurs far away 
from a tertiary referral center. On the other hand, the need for surgical and intensive care 
expertise, the non-negligible learning curve and the major social costs support the 
reservation of this technique to tertiary centers. The concept of territorial network (several
peripheral hospitals depending on one tertiary center) is part of this debate. As ECLS is at 
the frontier between cardiology, cardiac surgery and intensive care medicine, 
professionals involved in all these specialties are expected to contribute and develop 
shared recommendations. 
Interestingly, it emerged from our experience that the rate of bridge to heart transplantation 
is comparable among patients receiving E-CPR vs. the remainder veno-arterial ECLS 
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cases at our Institution (Table 3). The rate of long-term VAD implantation was even higher 
among refractory cardiac arrest patients. Such analysis is limited by low sample size and 
should be interpreted keeping in mind the heterogeneous composition of the non-cardiac 
arrest population (including patients receiving ECLS for early graft failure and post-
cardiotomy myocardial failure) and the different average age (younger among the E-CPR
patients). Nevertheless, this information suggests that urgent transplantation and long-
term VAD are as effective among rescued-cardiac arrest individuals as in the general 
ECLS population. Therefore, the E-CPR patients should be submitted to the same 
decisional criteria than conventional ECLS patients, although particular attention must be 
devoted to the assessment of brain death and nonsurvivable end-organ injury.  
One major finding of the present work consists in the demonstration of stable survival at 
the mid-term follow-up among patients who were discharged from the hospital. Concerning 
the assessment of quality-of-life, better scores were observed for Mental Health and 
related domains; lower scores were observed for the General Health and Vitality domains. 
This may be interpreted as the consequences at the early- to mid-term follow-up of long-
term hospitalization and ICU stay. The subtending disease, ICU-related neuropathy, 
hyponutrition and the high rate of complications may explain such finding. It is reasonable 
to expect improvements in these domains and more complete recovery at later intervals. 
Survivors to cardiac arrest using E-CPR showed herein worse health-related quality-of-life 
scores than the normal matched French population, as the expression of severe disease 
and prolonged hospitalization. Interestingly, our E-CPR patients presented better average 
scores in all SF-36 domains compared to previous studies over ECLS patients [13], veno-
venous ECMO patients of the CESAR study [14] and survivors to post-cardiotomy 
myocardial failure through ECLS [13] (Figure 3). Such finding may be attributed to different 
characteristics of the comparator populations. Namely, patients on veno-venous ECMO 
are particularly likely to experience particularly long and debilitating hospitalization in 
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critical care environment. The patients enrolled in the study by Wang and associates all 
presented post-cardiotomy myocardial failure and structural heart disease, with inherent 
negative prognostic significance [13]. Collectively, our data suggest that survivors to acute 
events thanks to E-CPR may attain satisfactory health-related quality-of-life compared to 
similar populations of critical care patients. Similarly, the SF-36 Mental and Physical 
summary scores were comparable to those obtained among survivors to cardiac arrest 
without E-CPR treatment [18]. The present paper reports for the first time measures of 
quality-of-life among patients surviving refractory cardiac arrest thanks to E-CPR. 
Therefore, the practice of E-CPR is justified by the possibility to achieve good functional 
results in the survivors. 
The present investigation is limited by retrospective analysis of data; such limitation is 
partially offset by the prospective inclusion of patients’ information into a dedicated 
database. Another limitation is the lack of a control group (survivors to cardiac arrest who 
did not receive E-CPR). On the other hand, we limited the inclusion to patients who 
received E-CPR during ongoing external cardiac massage. This allows focusing on a more
selected population than previous reports [5]. As a further minor limitation, the rate of 
thromboembolic and hemorrhagic complications is given in aggregate form. 
Conclusions.
Use of E-CPR is an effective strategy which allows saving lives in a population of severely 
compromised patients. This is probably the most challenging domain within an ECLS 
program. The survival at ECLS explantation reported herein is among the highest 
published so far. Patients who survive the initial cardiac arrest injury thanks to E-CPR may 
subsequently enter the same decision-making algorithm than patients who received ECLS 
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during non-cardiac arrest circumstances. Nonetheless, high rates of brain death and non-
survivable end-organ injury are common among patients rescued from cardiac arrest, and 
may preclude bridging to urgent transplantation or VAD in a significant proportion of cases. 
Overall, about one third of patients in our experience survived at both discharge and mid-
term follow-up. Remarkably, survival tends to remain stable after discharge. Health-related 
quality-of-life among survivors is better or comparable than in previous investigations over 
ECLS / ECMO recipients or cardiac arrest survivors. These findings support the practice of 
E-CPR, provided that adequate patients’ selection is performed in order to avoid 
unjustified employment of hospital resources. 
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Figure Legends 
Figure 1.  Study design. VA: Veno-Arterial. 
Figure 2. Actuarial (Kaplan-Meier) survival curve for patients receiving ECLS for refractory 
cardiogenic shock; in-hospital mortality is included. The grey interrupted lines depict the 
confidence limits for the estimate.
Figure 3. Comparison of SF-36 scores observed among patients enrolled in our study (red 
line, E-CPR) with the corresponding SF-36 scores obtained from patients who survived 
ARDS through veno-venous ECMO (CESAR study ECMO cohort from reference 14; 
yellow interrupted line, ECMO-CESAR), patients who survived post-cardiotomy myocardial 
failure through veno-arterial ECLS (from reference 13; green interrupted line, ECLS-
postcardiotomy). Comparison with normal age- and sex-matched French population is 
offered (blue continuous line, Control). PA: Physical Activity. RL: Role Limitation. PP: 
Physical Pain. GH: General Health. VT: Vitality. SA: Social Activity. MH: Mental Health. 
Central Picture Legend 
Survival curve for patients receiving E-CPR (follow-up: 15.6 ± 19.2 months). 
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Table 1. Descriptors of the study population. LVEF: Left Ventricular Ejection Fraction. 
SGOT: Serum Glutamic Oxaloacetic Transaminase. *Refers to any LVEF measurement 
available on the day of E-CPR implantation, including LVEF immediately after institution of 
support. §Refers to catecholamines administered while on support, excluding those 
administered during cardiopulmonary resuscitation. 
Characteristic 
Age (years) 47.6 ± 16 
Gender: Male/Female 30/19 (61.2%-38.8%) 
Body Surface Area (m2) 1.89 ± 0.23 
Site of cardiac arrest 
- In-hospital 
- Out-of-hospital 
43 (88%) 
6 (12%) 
Site of E-CPR implantation 
- Operative theater 
- ICU 
- Catheterization room 
- Other 
24 (49%) 
18 (36.7%) 
2 (4.1%) 
5 (10.2%) 
Indication to E-CPR ECLS 
- Cardiac disease 
- Respiratory disease 
- Trauma 
- Sepsis 
- Miscellaneous 
30 (61.2%) 
2 (4.1%) 
7 (14.3%) 
1 (2%) 
9 (18.4%) 
LVEF* (%) 22.8 ± 15.3 
No-flow time (min) 1.1 ± 2.9 
Low-flow time (min) 47.2 ± 33 
Inotropes§
- Dobutamine >5 γ/kg/min 
- Adrenaline >1 mg/h 
- Noradrenaline >1 mg/h 
18 (36.7%) 
16 (32.6%) 
25 (51%) 
pH 7.2 ± 0.3 
Lactate (mmol/l) 11.7 ± 6 
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Serum Creatinine (µmol/L) 144 ± 53 
SGOT (IU/L) 637 ± 961 
Troponin T 472 ± 1188 
SAPS Score 61.1 ± 29.2 
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Table 2.  Survivors vs. non-survivors at 30 days after implantation of E-CPR ECLS: 
univariate intergroup comparison of patient-related variables at the time of start of support. 
Characteristic Survivors (N=18) Non-survivors (N=31) p 
Gender: male 13 (72.2%) 17 (54.8%) 0.2 
Age (years) 44.9 ± 17.3 48.8 ± 15.3 0.2 
Site of implantation 
- Operative theater 
- Other 
11 (61%) 
 7 (39%) 
13 (41.9%) 
18 (58.1%) 
0.19 
SAPS Score 43.5 ± 21.5 70.3 ± 28.8 0.006 
Body temperature at E-
CPR implantation (°C) 
36 ± 1.9 34.7 ± 2.2 0.02 
Serum creatinine (µmol/L) 139 ± 53 148 ± 53 0.5 
Serum lactates (mmoL/L) 8.6 ± 4.4 12.8 ± 6.6 0.04 
pH 7.28 ± 0.3 7.2 ± 0.2 0.4 
Low-flow time 33.4 ± 15.6 52.9 ± 36.6 0.09 
No-flow time 0 1.6 ± 3.3 0.16 
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Table 3.  Rates of bridge to urgent heart transplantation or to VAD implantation: patients 
receiving E-CPR vs. those receiving veno-arterial ECLS during the same period under 
non-cardiac arrest circumstances. *p<0.001 (mean age comparison among cardiac arrest 
vs. non-cardiac arrest patients). 
Characteristic E-CPR patients ECLS patients – no 
cardiac arrest at 
implantation 
Overall series 
 - Urgent Heart Transplantation 
 - VAD 
 - Any 
4.1% 
4.1% 
8.2% 
4.8% 
1.9% 
6.7% 
Survivors at ECLS explantation only 
 - Urgent Heart Transplantation 
 - VAD 
 - Any 
9.5% 
9.5% 
19.4% 
9.8% 
3.8% 
13.6% 
Age (years) 47.6 ± 16* 55.5 ± 13.9* 
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Table 4.  Results of Quality-of-Life scores assessment among survivors at the average 
15.6 months follow-up. SD: Standard deviation. 100: best possible score.
Characteristic Mean ± SD 
Physical Activity score 70.8 ± 27.4 
Role Limitation score 63.6 ± 23.2 
Physical Pain score 81.3 ± 23.6 
General Health score 62.7 ± 16 
Vitality score 56.5 ± 18.8 
Social Activity score 74 ± 23 
Mental Health score 71.4 ± 17 
Physical Component Summary 45.2 ± 6.8 
Mental Component Summary 48.3 ± 7.7 
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